GlassScriptPhysician profile
John G Ladas
NPI 1992743611
$1,524.52
in general payments reported to CMS, 2019-2025
18 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $66.83 · 2021: $254 · 2022: $165 · 2023: $366 · 2024: $291 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $336.60 | 2020-2025 | Argos, Eysuvis, Clareon |
| Aerie Pharmaceuticals, INC. | $216.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $128.36 | 2019-2023 | |
| Shire North American Group INC | $122.76 | 2019 | |
| Abbvie INC. | $114.42 | 2023-2024 | |
| Rxsight INC | $97.23 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.30 | 2019-2021 | |
| Oyster Point Pharma, INC. | $67.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $66.23 | 2021-2024 | Cequa |
| Bausch & Lomb Americas INC. | $59.27 | 2022-2024 | Stellaris, Envista Mx60 Iol, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $54.40 | 2024 | Tecnis Simplicity |
| Dompe US, INC. | $46.48 | 2021-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $32.70 | 2024 | Xdemvy |
| Harrow Eye, LLC | $22.53 | 2025 | |
| Allergan, INC. | $21.65 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $17.49 | 2024 | Lensar Laser System |
| Glaukos Corporation | $16.76 | 2024 | Idose |
| Kala Pharmaceuticals, INC. | $16.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ladas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.